Details

NameSymbolSector
PHARMAIDS PHARMACEUTICALS LTD.PHARMAIDPharmaceuticals
Open
56.35
High
59.2
Low
55
Close
57.57
Volume
8554
Exchange
bse
Time
03-Oct-2025

Outlook

Score:

2

Rating:

RISKY

Candlestick Pattern

CandlepatternofPharmaidsPharmaceuticalsis
None
EstimatedStoplossofPharmaidsPharmaceuticalsis
55
PharmaidsPharmaceuticalshasa
Bullishℹ
pattern.
Formationof
None
candlepatternindicatesthetrenddirectionofPharmaidsPharmaceuticalsis
Unpredictableℹ
.

Trend

PharmaidsPharmaceuticalsisin
Sideways trendℹ
.
PriceofPharmaidsPharmaceuticalsis
Downℹ
by

4.95

%.
Target
Buy@

55.47

Sell@

68.17

Current@

57.57

Volume

PharmaidsPharmaceuticalshasseen
Moderateℹ
volumeoftrades.
ThevolumetrendforPharmaidsPharmaceuticalsis
Bearishℹ
,buttheparticipantsare
Weak Sellersℹ
ThetradevolumeofPharmaidsPharmaceuticalsis

Up

by

16.96

%

Valuation

ThecurrentmarketpriceofPharmaidsPharmaceuticalsis
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth119crandtotalassetsworth119cr,thebalancesheetofPharmaidsPharmaceuticalsis:
Balancedℹ
.
Cashflow
PharmaidsPharmaceuticalshas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 2cr

.Itis
Upℹ
by

71.43

%.
27.08% i.e. ₹ 13cr spent in operatingℹ
25% i.e. ₹ 12cr spent in investingℹ
47.92% i.e. ₹ 23cr earned in financingℹ
0% in otherℹ
PharmaidsPharmaceuticalshas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 7cr

.Itis
Downℹ
by

158.33

%.
6.21% i.e. ₹ 10cr spent in operatingℹ
45.96% i.e. ₹ 74cr spent in investingℹ
47.83% i.e. ₹ 77cr earned in financingℹ
0% in otherℹ
Income
TheincomeofPharmaidsPharmaceuticalsis

₹ 6cr

and

Loss

is:

₹ 5cr

PharmaidsPharmaceuticalsLossesincreasedby:

25

%andIncomeisUpby:

50

%
TheincomeofPharmaidsPharmaceuticalsis

₹ 4cr

and

Loss

is:

₹ 4cr

PharmaidsPharmaceuticalsLossesincreasedby:

33.33

%andIncomeisUpby:

0

%
TheincomeofPharmaidsPharmaceuticalsis

₹ 4cr

and

Loss

is:

₹ 3cr

PharmaidsPharmaceuticalsLossesincreasedby:

50

%andIncomeisDownby:

20

%
By using this site you agree to the use of cookies to deliver a better site experience.